東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Drug delivery to the eye for treatme...

Lin, Cheng-Wen.

FindBook

Google Book

Amazon

博客來

Drug delivery to the eye for treatment of primary open-angle glaucoma.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Drug delivery to the eye for treatment of primary open-angle glaucoma./
作者:	Lin, Cheng-Wen.
面頁冊數:	167 p.
附註:	Adviser: Fan Yuan.
Contained By:	Dissertation Abstracts International68-05B.
標題:	Engineering, Biomedical. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3264043
ISBN:	9780549024293

Drug delivery to the eye for treatment of primary open-angle glaucoma.
Lin, Cheng-Wen.

Drug delivery to the eye for treatment of primary open-angle glaucoma. - 167 p.

Adviser: Fan Yuan.

Thesis (Ph.D.)--Duke University, 2006.

Drug delivery to the eye presents significant challenges as topically- and systemically-applied drugs hardly reach target tissues, such as the trabecular meshwork (TM). Relentless efforts have been made on improving ocular drug bioavailability through either increasing drug residence time or modulation of corneal epithelia, but without significant success. Since direct and non-invasive assessments of human ocular bioavailability are practically impossible to date, there is no effective way to evaluate the effectiveness of different delivery strategies. A systematic study of drug transport across the major barriers in the eye may provide a better understanding of how these barriers affect drug transport and how they may be overcome to improve overall ocular drug bioavailability.

ISBN: 9780549024293Subjects--Topical Terms:

1017684
Engineering, Biomedical.

Drug delivery to the eye for treatment of primary open-angle glaucoma.
LDR:02992nam 2200301 a 45 001 951808
005 20110617
008 110617s2006 ||||||||||||||||| ||eng d
020 $a 9780549024293
035 $a (UMI)AAI3264043
035 $a AAI3264043
040 $a UMI $c UMI
100 1 $a Lin, Cheng-Wen. $3 1275815
245 1 0 $a Drug delivery to the eye for treatment of primary open-angle glaucoma.
300 $a 167 p.
500 $a Adviser: Fan Yuan.
500 $a Source: Dissertation Abstracts International, Volume: 68-05, Section: B, page: 3200.
502 $a Thesis (Ph.D.)--Duke University, 2006.
520 $a Drug delivery to the eye presents significant challenges as topically- and systemically-applied drugs hardly reach target tissues, such as the trabecular meshwork (TM). Relentless efforts have been made on improving ocular drug bioavailability through either increasing drug residence time or modulation of corneal epithelia, but without significant success. Since direct and non-invasive assessments of human ocular bioavailability are practically impossible to date, there is no effective way to evaluate the effectiveness of different delivery strategies. A systematic study of drug transport across the major barriers in the eye may provide a better understanding of how these barriers affect drug transport and how they may be overcome to improve overall ocular drug bioavailability.
520 $a To this end, the transscleral and transcorneal permeability and diffusion coefficients of a potential TM drug, ethacrynic acid (ECA), were measured in ex vivo porcine eyes. The cytotoxicity of ECA on porcine corneal epithelial cells was also determined in vitro. A two-dimensional, axisymmetric mathematical model based on the anatomy of a human eye was also developed to simulate drug transport in the anterior chamber of the eye. A cellular pharmacokinetic and pharmacodynamic model is also developed to predict ECA toxicities for optimizing treatments of primary open-angle glaucoma (POAG).
520 $a In summary, the results indicated that increasing drug residence time in the precorneal region may have significant improvements on ocular drug bioavailability while modulation of corneal epithelia may have negligible effects. Although the majority of these data are for ECA, the models presented in this study, such as the binding-diffusion model, the ocular pharmacokinetic model for drug transport in the anterior chamber of the eye, and the cellular pharmacokinetic and pharmacodynamic model, can be used for evaluating other potential drugs as well. These models may also be useful for directing future delivery approaches to improve ocular bioavailability for treatments of diseases in the anterior chamber of the eye.
590 $a School code: 0066.
650 4 $a Engineering, Biomedical. $3 1017684
650 4 $a Health Sciences, Ophthalmology. $3 1019445
690 $a 0381
690 $a 0541
710 2 $a Duke University. $3 569686
773 0 $t Dissertation Abstracts International $g 68-05B.
790 $a 0066
790 1 0 $a Yuan, Fan, $e advisor
791 $a Ph.D.
792 $a 2006
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3264043